Trump’s Ozempic tariffs, Zepbound on Medicare, and rising drug prices: Pharma news roundup

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when prescribed to treat sleep apnea. The cost of prescription drugs is set to climb in 2025 and beyond, according to a report from the investment bank TD Cowen. And President-elect Donald Trump’s…

Read more…

​El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when prescribed to treat sleep apnea. The cost of prescription drugs is set to climb in 2025 and beyond, according to a report from the investment bank TD Cowen. And President-elect Donald Trump’s…Read more…